• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Pharmacy Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 9 (2025)
Volume Volume 8 (2024)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 7 (2023)
Volume Volume 6 (2022)
Volume Volume 5 (2021)
Volume Volume 4 (2020)
Volume Volume 3 (2019)
Volume Volume 2 (2018)
Volume Volume 1 (2017)
Yousefi, R. (2024). Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Journal of Advanced Pharmacy Research, 8(3), 176-187. doi: 10.21608/aprh.2024.288238.1268
Roohallah Yousefi. "Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs)". Journal of Advanced Pharmacy Research, 8, 3, 2024, 176-187. doi: 10.21608/aprh.2024.288238.1268
Yousefi, R. (2024). 'Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs)', Journal of Advanced Pharmacy Research, 8(3), pp. 176-187. doi: 10.21608/aprh.2024.288238.1268
Yousefi, R. Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Journal of Advanced Pharmacy Research, 2024; 8(3): 176-187. doi: 10.21608/aprh.2024.288238.1268

Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Article 6, Volume 8, Issue 3, July 2024, Page 176-187  XML PDF (1.43 MB)
Document Type: Research Article
DOI: 10.21608/aprh.2024.288238.1268
View on SCiNiTO View on SCiNiTO
Author
Roohallah Yousefi email orcid
Behbahan Faculty of Medical Sciences, Iran
Abstract
Objectives: The nucleic acid-binding cleft in HIV-1 reverse transcriptase (HIV-1 RT) is essential because of its interactions with the polymerase and RNase H active sites. Studying its binding sites for nucleoside reverse transcriptase inhibitors (NRTIs) is crucial for understanding how to effectively select drug compounds, properly administer drugs, and prevent drug resistance. Materials and Methods: We conducted docking studies using Molegro Visual Docker, and then we used SwissADME software to analyze the physicochemical properties and pharmacokinetics of the compounds. Results: The molecular docking results of the studied compounds with the HIV-1 reverse transcriptase model (6ASW) showed that zalcitabine has the highest ligand efficiency for the enzyme model. The binding sites of the studied compounds were investigated, revealing that all the compounds bind to sequences containing amino acids 34, Val 35, and Val 60, or connect to a binding site containing amino acids Val 90, Gln 91, Leu 92, Gln 161, Ser 162, Thr 165, and Gln 182 in the p66 subunit. Only Zidovudine binds to the sequence of amino acids Asp 110, Tyr 183, Asp 186, Lys 220, Gln 222, Met 230, and Gly 231, which are in the active site of the enzyme. Conclusions: We emphasize the crucial role of NRTIs' affinity for the enzyme in inhibiting HIV-1 reverse transcriptase. It is important to monitor and understand resistance mutations of the HIV-1 reverse transcriptase enzyme for effective drug administration strategies.
Keywords
HIV-1; Reverse transcriptase; Molecular docking
Main Subjects
Section D: Clinical Pharmacy & Pharmacology
Statistics
Article View: 294
PDF Download: 249
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.